Skip to main content

Table 3 Summary of the progress of the cases

From: Blood purification therapies in methotrexate-induced acute kidney injury: four case reports

  Data before the start of blood purification Blood purification method Column used Average reduction ratea Days required for MTX to reach 0.1 μmol/L Days required for serum Cre to decrease to its previous value
MTX (μmol/L) Serum Cre (mg/dL)
Case 1 31.0 3.20 HD → HDF PES-15Sα® HD 58.3 ± 6.17% HDF 40.0 ± 5.63% 18 days 40 days
Case 2 23.0 1.80 HP CHS-350® 55.3 ± 11.6% 14 days 18 days
Case 3 62.4 3.75 HD + HP VPS-13HA®/PES-13Sα® (absorption column CHS-350®) 56.1 ± 12.2% 20 days Approximately 50 days
Case 4 183.6 4.23 HD + HP VPS-13HA® (absorption column CHS-350®) 63.2%
  1. MTX methotrexate, eGFR estimated glomerular filtration rate, Cre creatinine, HD hemodialysis, HDF hemodialysis filtration, HP hemoperfusion. PES-15Sα® and PES-13Sα® polyethersulfone dialyzer, VPS-13HA® vitamin E-coated polysulfone dialyzer, Hemosorba CHS-350® activated chacol column, Sublood®-BSG substitution fluid
  2. aReduction rate is calculated by dividing the difference of MTX blood concentration before and after blood purification by MTX blood concentration before blood purification